WallStreetZenWallStreetZen

NASDAQ: CUE
Cue Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CUE

Based on 4 analysts offering 12 month price targets for Cue Biopharma Inc.
Min Forecast
$2.00+250.88%
Avg Forecast
$4.75+733.33%
Max Forecast
$10.00+1,654.39%

Should I buy or sell CUE stock?

Based on 4 analysts offering ratings for Cue Biopharma Inc.
Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CUE stock forecasts and price targets.

CUE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-20
lockedlocked$00.00+00.00%2024-07-26
lockedlocked$00.00+00.00%2024-07-26
lockedlocked$00.00+00.00%2024-04-09

1 of 1

Forecast return on equity

Is CUE forecast to generate an efficient return?
Company
-197.23%
Industry
-702.41%
Market
48.37%
CUE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CUE forecast to generate an efficient return on assets?
Company
-100.75%
Industry
26.35%
CUE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CUE earnings per share forecast

What is CUE's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.87
Avg 2 year Forecast
-$0.73
Avg 3 year Forecast
-$0.65

CUE revenue forecast

What is CUE's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$11.5M+38.38%
Avg 2 year Forecast
$8.4M+1.7%
Avg 3 year Forecast
$18.0M+116.97%
CUE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CUE revenue growth forecast

How is CUE forecast to perform vs Biotechnology companies and vs the US market?
Company
23.11%
Industry
34.51%
Market
9.31%
CUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CUE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CUE$0.57$4.75+733.33%Strong Buy
DARE$3.24$40.33+1,144.85%Strong Buy
ACST$2.73N/AN/A
AEON$0.71$5.00+609.22%Buy
VYNE$1.83$5.75+214.21%Buy
View Top Biotech Stocks

Cue Biopharma Stock Forecast FAQ

Is Cue Biopharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CUE) stock is to Strong Buy CUE stock.

Out of 4 analysts, 2 (50%) are recommending CUE as a Strong Buy, 2 (50%) are recommending CUE as a Buy, 0 (0%) are recommending CUE as a Hold, 0 (0%) are recommending CUE as a Sell, and 0 (0%) are recommending CUE as a Strong Sell.

If you're new to stock investing, here's how to buy Cue Biopharma stock.

What is CUE's earnings growth forecast for 2024-2026?

(NASDAQ: CUE) Cue Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.58%.

Cue Biopharma's earnings in 2024 is -$46,957,000.On average, 4 Wall Street analysts forecast CUE's earnings for 2024 to be -$42,198,077, with the lowest CUE earnings forecast at -$58,371,979, and the highest CUE earnings forecast at -$26,267,391. On average, 4 Wall Street analysts forecast CUE's earnings for 2025 to be -$35,631,229, with the lowest CUE earnings forecast at -$41,833,252, and the highest CUE earnings forecast at -$26,267,391.

In 2026, CUE is forecast to generate -$31,457,632 in earnings, with the lowest earnings forecast at -$48,156,883 and the highest earnings forecast at -$20,430,193.

What is CUE's revenue growth forecast for 2024-2026?

(NASDAQ: CUE) Cue Biopharma's forecast annual revenue growth rate of 23.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.51%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.31%.

Cue Biopharma's revenue in 2024 is $8,296,000.On average, 3 Wall Street analysts forecast CUE's revenue for 2024 to be $558,425,268, with the lowest CUE revenue forecast at $310,344,356, and the highest CUE revenue forecast at $963,137,657. On average, 4 Wall Street analysts forecast CUE's revenue for 2025 to be $410,403,657, with the lowest CUE revenue forecast at $97,286,632, and the highest CUE revenue forecast at $1,155,278,755.

In 2026, CUE is forecast to generate $875,579,688 in revenue, with the lowest revenue forecast at $194,573,264 and the highest revenue forecast at $2,188,949,220.

What is CUE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CUE) forecast ROA is -100.75%, which is lower than the forecast US Biotechnology industry average of 26.35%.

What is CUE's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CUE price target, the average CUE price target is $4.75, with the highest CUE stock price forecast at $10.00 and the lowest CUE stock price forecast at $2.00.

On average, Wall Street analysts predict that Cue Biopharma's share price could reach $4.75 by Aug 20, 2025. The average Cue Biopharma stock price prediction forecasts a potential upside of 733.33% from the current CUE share price of $0.57.

What is CUE's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CUE) Cue Biopharma's current Earnings Per Share (EPS) is -$0.98. On average, analysts forecast that CUE's EPS will be -$0.87 for 2024, with the lowest EPS forecast at -$1.20, and the highest EPS forecast at -$0.54. On average, analysts forecast that CUE's EPS will be -$0.73 for 2025, with the lowest EPS forecast at -$0.86, and the highest EPS forecast at -$0.54. In 2026, CUE's EPS is forecast to hit -$0.65 (min: -$0.99, max: -$0.42).

What is CUE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CUE) forecast ROE is -197.23%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.